

Alameda Alliance for Health
1240 South Loop Road
Alameda, CA 94502

Location: Cisco Webex,
Meeting ID: 2483 728 3909
Password: Afz2qMm7KY6

IMPORTANT PUBLIC HEALTH AND SAFETY MESSAGE REGARDING PARTICIPATION AT ALAMEDA ALLIANCE FOR HEALTH COMMITTEE MEETINGS

STATE OR LOCAL OFFICIALS CONTINUE TO IMPOSE OR RECOMMEND MEASURES TO PROMOTE SOCIAL DISTANCING. AS A RESULT OF THE COVID-19 VIRUS, AND RESULTING ORDERS AND DIRECTION FROM THE PRESIDENT OF THE UNITED STATES, THE GOVERNOR OF THE STATE OF CALIFORNIA, AND THE ALAMEDA COUNTY HEALTH OFFICER, THE PUBLIC WILL NOT BE PERMITTED TO PHYSICALLY ATTEND THE ALAMEDA ALLIANCE FOR HEALTH MEETING TO WHICH THIS AGENDA APPLIES.

YOU MAY SUBMIT COMMENTS ON ANY AGENDA ITEM OR ON ANY ITEM NOT ON THE AGENDA, IN WRITING VIA MAIL TO "ATTN: ALLIANCE PHARMACEUTICAL AND THERAPEUTICS COMMITTEE" 1240 SOUTH LOOP ROAD, ALAMEDA, CA 94502; OR THROUGH E-COMMENT AT aasejo@alamedaalliance.org. YOU MAY WATCH THE MEETING LIVE BY LOGGING IN VIA COMPUTER AT THE FOLLOWING LINK: <https://alamedaalliance.webex.com/alamedaalliance> OR MAY LISTEN TO THE MEETING BY CALLING IN TO THE FOLLOWING TELEPHONE NUMBER: 1-408-418-9388. IF YOU USE THE LINK AND PARTICIPATE VIA COMPUTER, YOU MAY, THROUGH THE USE OF THE CHAT FUNCTION, REQUEST AN OPPORTUNITY TO SPEAK ON ANY AGENDIZED ITEM, INCLUDING GENERAL PUBLIC COMMENT. YOUR REQUEST TO SPEAK MUST BE RECEIVED BEFORE THE ITEM IS CALLED ON THE AGENDA. IF YOU PARTICIPATE BY TELEPHONE, YOU MAY SUBMIT ANY COMMENTS VIA THE E-COMMENT EMAIL ADDRESS DESCRIBED ABOVE OR PROVIDE COMMENT [DURING THE MEETING AT THE END OF EACH TOPIC](#).

PLEASE NOTE: THE ALAMEDA ALLIANCE FOR HEALTH IS MAKING EVERY EFFORT TO FOLLOW THE SPIRIT AND INTENT OF THE BROWN ACT AND OTHER APPLICABLE LAWS REGULATING THE CONDUCT OF PUBLIC MEETINGS, IN ORDER TO MAXIMIZE TRANSPARENCY AND PUBLIC ACCESS. DURING EACH AGENDA ITEM, YOU WILL BE PROVIDED A REASONABLE AMOUNT OF TIME TO PROVIDE PUBLIC COMMENT. THE COMMITTEE WOULD APPRECIATE, HOWEVER, IF COMMUNICATIONS OF PUBLIC COMMENTS RELATED TO ITEMS ON THE AGENDA, OR ITEMS NOT ON THE AGENDA, ARE PROVIDED PRIOR TO THE COMMENCEMENT OF THE MEETING.

AGENDA

| ITEM | DESCRIPTION | TIME | VOTE |
|------|--|------|--------|
| I) | Call to order <i>Steve O'Brien, MD, Chief Medical Officer - Alameda Alliance</i> <ul style="list-style-type: none"> Agenda Overview | | 2 min |
| II) | Informational Updates <i>Steve O'Brien, MD, Chief Medical Officer - Alameda Alliance</i> <i>Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda Alliance</i> <ul style="list-style-type: none"> Medical-RX Update COVID-19 Update CalAIM ECM/ILOS/MOT Update BH Update | | 10 min |
| III) | Pharmacy Utilization Reports (Quarter 3, 2021) <i>Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda Alliance</i> <ul style="list-style-type: none"> Top 50 Drugs by Cost Top 100 PA Reviewed Drugs | | 5 min |

IV) E-Voting Material/Consent Agenda

The following items have been sent to the voting committee for review via E-voting

Rahel Negash, PharmD, Pharmacist, Alameda Alliance

(All matters listed on the Consent Calendar are to be approved with one motion unless a member of the P&T Committee removes an item for separate action. Any consent calendar item for which separate action is requested shall be heard as the next Agenda item in closed session.)

| Monographs/Class Reviews | Changes |
|---|---|
| Ketone test strips (abbrev) | <ul style="list-style-type: none"> No changes |
| Topical Agents for Actinic Keratosis | <ul style="list-style-type: none"> No changes |
| Multi vitamins with fluoride | <ul style="list-style-type: none"> No changes |
| Gout | <ul style="list-style-type: none"> No changes |
| Fluoride dental preps | <ul style="list-style-type: none"> No changes |
| Physician Administered Drug Guidelines | Changes |
| Veklury | <ul style="list-style-type: none"> Change wording defining hospitalization requirement |
| Neuromyelitis Optica Spectrum Disorder (NMOSD) Agents | <ul style="list-style-type: none"> Add new rituximab biosimilar Riabni. Add language to address biologic reference drug not having the same indications as the biosimilar |
| Injectable/Specialty Medications | <ul style="list-style-type: none"> Add language to address biologic reference drug not having the same indications as the biosimilar |
| Oral and Injectable Oncology Medications | <ul style="list-style-type: none"> Add language to address biologic reference drug not having the same indications as the biosimilar |
| Tepezza | <ul style="list-style-type: none"> Add endocrinologist as physician type to prescribers allowed |
| Medication Request Guidelines | Changes |
| Diclofenac sodium (Solaraze) 3% gel (part of Topical Agents for Actinic Keratosis class review) | <ul style="list-style-type: none"> Update language for clarity |
| Oral and Injectable Oncology Medications | <ul style="list-style-type: none"> Add language to address biologic reference drug not having the same indications as the biosimilar |
| Injectable/Specialty Medications | <ul style="list-style-type: none"> Add language to address biologic reference drug not having the same indications as the biosimilar Add biosimilar statement for reauthorization |

15 min

E
V

| | |
|--|---|
| Brand Medications When a Generic or Biosimilar is Available | <ul style="list-style-type: none"> • Add language to address biologic reference drug not having the same indications as the biosimilar • Correct the spelling of biosimilar |
| Otezla (apremilast) for Behcet Disease | <ul style="list-style-type: none"> • Correct spelling of “Behcet” • Add clarifying language to specify one topical steroid |
| Fentanyl Citrate | <ul style="list-style-type: none"> • Change brand/generic status of Fentora. • Minor edits to criteria and criteria statement wording |
| dalfampridine (Ampyra) | <ul style="list-style-type: none"> • Adjust CrCl baseline timeframe |
| Prior Authorization Exception | <ul style="list-style-type: none"> • Broaden the definition of “mental and/or physical” with additional qualifiers |
| Proton Pump Inhibitors (PPIs) | <ul style="list-style-type: none"> • Minor wording changes in criteria and criteria statement |
| Endari | <ul style="list-style-type: none"> • Move highlighted sentence up to appear in bulleted format |
| Topical Diclofenac | <ul style="list-style-type: none"> • Add Licart to coverage duration section |
| Step Therapy Exception | <ul style="list-style-type: none"> • No changes |
| Botulinum Toxins A&B | <ul style="list-style-type: none"> • No changes |
| Blood Glucose Testing Supplies | <ul style="list-style-type: none"> • No changes |
| Oral and Non-Oral Contraceptives | <ul style="list-style-type: none"> • No changes |
| Acthar Gel Criteria | <ul style="list-style-type: none"> • No changes |
| Ranolazine ER (Ranexa) | <ul style="list-style-type: none"> • No changes |
| Temazepam (Restoril) | <ul style="list-style-type: none"> • No changes |
| Thalomid (thalidomide) | <ul style="list-style-type: none"> • No changes |
| Rayaldee (calcifediol ER) | <ul style="list-style-type: none"> • No changes |
| Korlym (mifepristone) | <ul style="list-style-type: none"> • No changes |
| Butorphanol (Stadol NS) | <ul style="list-style-type: none"> • No changes |
| Interim Formulary Updates | |
| <ul style="list-style-type: none"> • See p. in packet | |
| Pharmacy Policy & Procedure Updates | |
| <ul style="list-style-type: none"> • RX-003 Exception Review Process • RX-012 DU Policies- Pharmacy Portal DU Access | |
| P&T Meeting Minutes | |
| <ul style="list-style-type: none"> • P&T Meeting Minutes Q3 September 21, 2021 | |

ADJOURN TO CLOSED SESSION (Pursuant to California Government Code Title 5, §54954.5(h))

Discussion will Concern: Review and Recommendations to changes to the AAH Formulary and utilization management for selected drug classes
Estimated Date of Public Disclosure: 12/21/2021 (formulary changes only; no trade secrets will be disclosed).

V) New Business

Natalee Felten, PharmD, Pharmacist, PerformRx

- Physician Administered Drug (PAD) Medication Request Guideline Document
- New:**
- Botulinum Toxins A&B

VI) PAD Revisions

Natalee Felten, PharmD, Pharmacist, PerformRx

Revise:

- Tepezza
- Viltepsa

VII) Class Reviews, Monographs, and Recommendations

Natalee Felten, PharmD, Pharmacist, PerformRx

1. Androgens
2. Wegovy monograph
3. Pneumonia vaccine monograph/comparator
4. Urinary antispasmodics

45
min

VIII) Medication Request Guidelines

Rahel Negash, PharmD, Pharmacist, Alameda Alliance

1. Biologic Agents for Nasal Polyps
2. Interleukin Receptor Antagonists for Asthma
3. Isotretinoin capsules
4. Lupron Depot and Lupron Depot-Ped
5. Injectable Methotrexate
6. Agents for Atopic Dermatitis
7. Oral Anti-Fungals
8. Growth Hormone

IX) Summary of Closed Session

Helen Lee, PharmD, MBA, Senior Pharmacy Director – Alameda Alliance

RECONVENE IN OPEN SESSION

| ITEM | DESCRIPTION | TIME | VOTE |
|------|--|------|------|
| X) | Informational Updates on New Developments in Pharmacy <i>Natalee Felten, PharmD, Pharmacist, PerformRx</i> | | 2 |
| | • New Product Review | | min |

- | | | |
|-------|------------------------------|-------|
| XI) | Old Business | 0 min |
| | • None | |
| XII) | Public Comment | 0 min |
| XIII) | Adjournment | |
| | • P&T Committee Member Forms | |

ACTION / FOLLOW-UP ITEMS

| ITEM | DUE DATE | RESPONSIBLE |
|------|----------|-------------|
| | | |
| | | |
| | | |

FUTURE P&T MEETINGS

| NEXT MEETING | 2022 P&T MEETINGS |
|-------------------------------|-----------------------------------|
| March 15 th , 2022 | June 21 st , 2022 |
| | September 20 th , 2022 |
| | December 20 th , 2022 |

The Alameda Alliance for Health Pharmacy & Therapeutics Committee welcomes you to its meetings and your interest is appreciated. Due to the pandemic (COVID-19), this meeting is held as a video conference call only. If you wish to speak on a matter on the agenda, you will have the opportunity to do so at the end of each topic. If you wish to speak on a matter not on the agenda, please wait until the Chair asks for public comments at the end of the regular agenda. Please be brief and limit your comments to the specific subject under discussion.

Note: Only matters within the jurisdiction of the Alameda Alliance for Health Pharmacy & Therapeutics Committee may be addressed. If necessary, the Chair may limit the total time to be devoted to public comment on any item, and the time allotted to individual speakers, to ensure sufficient time for the consideration of all matters on the agenda.

This meeting is wheelchair accessible. Please contact Helen Lee at 510-747- 6241 or hlee@alamedaalliance.org at least 72 hours before the meeting to request agenda materials in an alternative format, or any other reasonable disability-related accommodations or services that may be necessary for you to participate in and enjoy the benefits of the meeting.